Elena Verzoni Selected Research

tivozanib

1/2021	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
12/2020	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
1/2020	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
8/2019	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elena Verzoni Research Topics

Disease

77	Renal Cell Carcinoma (Grawitz Tumor) 12/2022 - 01/2007
29	Neoplasms (Cancer) 12/2022 - 01/2006
12	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2014
10	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2015
9	Disease Progression 01/2022 - 01/2007
6	Kidney Neoplasms (Kidney Cancer) 10/2022 - 01/2014
4	Human Influenza (Influenza) 01/2021 - 10/2018
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2022 - 01/2006
3	Carcinoma (Carcinomatosis) 01/2022 - 06/2012
3	Circulating Neoplastic Cells 02/2020 - 10/2018
3	Hypertension (High Blood Pressure) 01/2020 - 04/2014
2	Fatigue 01/2019 - 04/2014
2	Hypothyroidism 01/2019 - 01/2019
2	Diarrhea 01/2019 - 04/2014
1	Breast Neoplasms (Breast Cancer) 12/2022
1	Lymphoma (Lymphomas) 12/2022
1	Febrile Neutropenia 01/2022
1	Seminoma 01/2022
1	Bone Resorption 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 11/2021
1	Pain (Aches) 10/2020
1	Stomatitis 05/2020
1	Mucositis 05/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	COVID-19 01/2020
1	Rare Diseases (Rare Disease) 09/2019
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Inflammation (Inflammations) 01/2019

Drug/Important Bio-Agent (IBA)

15	Sorafenib (BAY 43-9006)FDA Link 12/2020 - 01/2007
13	Immune Checkpoint InhibitorsIBA 10/2022 - 09/2016
12	cabozantinibIBA 10/2022 - 01/2016
11	Sunitinib (Sutent)FDA Link 01/2021 - 10/2011
9	Tyrosine Kinase InhibitorsIBA 11/2021 - 01/2014
9	Everolimus FDA Link 05/2020 - 11/2011
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2012
6	pazopanib FDA Link 01/2020 - 11/2014
4	NivolumabIBA 10/2022 - 09/2016
4	tivozanibIBA 01/2021 - 08/2019
4	Axitinib (AG 013736)IBA 12/2020 - 11/2011
4	Biological ProductsIBA 01/2020 - 01/2006
4	temsirolimus FDA Link 06/2015 - 11/2011
3	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2021 - 10/2018
3	TOR Serine-Threonine KinasesIBA 05/2020 - 01/2015
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 01/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2015
3	abirateroneIBA 07/2019 - 06/2016
2	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 10/2014
2	Angiogenesis InhibitorsIBA 11/2021 - 01/2014
2	Pharmaceutical PreparationsIBA 06/2021 - 06/2016
2	pembrolizumabIBA 12/2020 - 09/2016
2	atezolizumabIBA 01/2020 - 09/2016
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2015
2	Hemoglobins (Hemoglobin)IBA 12/2019 - 06/2015
2	LigandsIBA 07/2019 - 10/2016
2	enzalutamideIBA 07/2019 - 11/2018
2	Transaminases (Aminotransferases)IBA 01/2019 - 01/2019
2	CytokinesIBA 10/2018 - 04/2014
2	Abiraterone AcetateIBA 09/2016 - 10/2015
2	Docetaxel (Taxotere)FDA Link 06/2016 - 10/2014
2	Phosphotransferases (Kinase)IBA 05/2016 - 06/2015
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2014 - 01/2009
2	Capecitabine (Xeloda)FDA Link 10/2014 - 01/2009
2	Irinotecan (Camptosar)FDA LinkGeneric 10/2014 - 01/2009
1	99mTc-octreotideIBA 12/2022
1	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2022
1	pentetreotide (OctreoScan)FDA Link 12/2022
1	Octreotide (Sandostatin)FDA LinkGeneric 12/2022
1	EDDA (NiEDDA)IBA 12/2022
1	IpilimumabIBA 10/2022
1	DNA Polymerase IIIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Exonucleases (3' 5' Exonuclease)IBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021
1	Thyroid HormonesIBA 01/2021
1	Radium-223IBA 10/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	olaparibIBA 01/2020
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2020
1	E-SelectinIBA 01/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	OsteopontinIBA 01/2020

Therapy/Procedure

40	Therapeutics 10/2022 - 09/2010
12	Immunotherapy 01/2022 - 09/2016
9	Castration 10/2020 - 10/2015
6	Nephrectomy 01/2021 - 01/2014
4	Drug Therapy (Chemotherapy) 01/2022 - 02/2014
3	Aftercare (After-Treatment) 01/2022 - 01/2018
3	Metastasectomy 11/2019 - 10/2018
1	Radiotherapy 01/2022
1	Orchiectomy (Orchidectomy) 01/2022
1	Precision Medicine 01/2022
1	Organ Transplantation 11/2021
1	Immunomodulation 01/2021
1	Oral Hygiene (Dental Hygiene) 05/2020